KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to $6.1 million.

  • Biocryst Pharmaceuticals' Beginning Cash Balance fell 85.37% to $17.7 million in Q4 2015 from the same period last year, while for Dec 2015 it was $25.6 million, marking a year-over-year increase of 21.15%. This contributed to the annual value of $6.1 million for FY2024, which is 96.84% down from last year.
  • Per Biocryst Pharmaceuticals' latest filing, its Beginning Cash Balance stood at $6.1 million for FY2024, which was down 96.84% from $193.8 million recorded in FY2023.
  • Biocryst Pharmaceuticals' Beginning Cash Balance's 5-year high stood at $201.5 million during FY2022, with a 5-year trough of -$233.4 million in FY2021.
  • For the 3-year period, Biocryst Pharmaceuticals' Beginning Cash Balance averaged around $133.8 million, with its median value being $193.8 million (2023).
  • As far as peak fluctuations go, Biocryst Pharmaceuticals' Beginning Cash Balance spiked by 186.34% in 2022, and later crashed by 96.84% in 2024.
  • Over the past 5 years, Biocryst Pharmaceuticals' Beginning Cash Balance (Yearly) stood at -$158.6 million in 2020, then plummeted by 47.13% to -$233.4 million in 2021, then soared by 186.34% to $201.5 million in 2022, then declined by 3.82% to $193.8 million in 2023, then crashed by 96.84% to $6.1 million in 2024.